Spots Global Cancer Trial Database for SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Official Title: SHR7390 in the Treatment of Metastatic Hormone-Resistant Prostate Cancer That Failed Previous Docetaxel and New Endocrine Therapy
Study ID: NCT04676607
Interventions
Study Description
Brief Summary: This trial aims to prospectively assess the safety and efficiency of SHR7390 in metastatic castration-resistant prostate cancer
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
Contact Details
Name: Hongqian Guo
Affiliation: Department of Urology, Drum Tower Hospital, Medical School of Nanjing University
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
